Biogen Inc

Biogen Inc. (www.biogen.com) is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.

• Medicare Limits Payments for Biogen's Alzheimer's Drug (US.BIIB) - 08 aprilie 2022
• Eli Lilly: FDA refuza sa aprobe noul medicament contra bolii Alzheimer - 20 ianuarie 2023
• Eli Lilly renunta la testarea unui tratament contra bolii Alzheimer - 09 martie 2023
• Biogen: aviz accelerat pentru un nou tratament contra bolii Alzheimer - 09 ianuarie 2023
• Biogen Stock Slides On Q1 Earnings Miss; CEO Michel Vounatsos Exits (US.BIIB) - 03 mai 2022
• Biogen (US.BIIB) Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint - 03 februarie 2022
• Alzheimer's drug study yields positive results, say makers Eisai and Biogen - 29 septembrie 2022
• Biogen Inc